The DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.
IgG Fc engineering to modulate antibody effector functions
Open accessAbstract
Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An important aspect of antibodies is their ability to bind antigen while at the same time recruit immune effector functions. The majority of approved recombinant monoclonal antibody therapies are of the human IgG1 subclass, which can engage both humoral and cellular components of the immune system. The wealth of information generated about antibodies has afforded investigators the ability to molecularly engineer antibodies to modulate effector functions. Here, we review various antibody engineering efforts intended to improve efficacy and safety relative to the human IgG isotype. Further, we will discuss proposed mechanisms by which engineering approaches led to modified interactions with immune components and provide examples of clinical studies using next generation antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In fact, IgG Fc glycosylation is critical to many functions of antibody effectors through modulating Fc-FcγR interactions [220].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,369
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature reviews. Immunology · doi:10.1038/nri1837 · Cited by 1,124
THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE
Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U. S., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 903
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 824
Cited by
Sorted by citations
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
Vivier, É., Rebuffet, L., Narni-Mancinelli, É., Cornen, S., Igarashi, R., & Fantin, V. R. (2024) · Nature · doi:10.1038/s41586-023-06945-1 · Cited by 496
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 480
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 321
Kruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.2 · Cited by 312
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 328
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00690-x · Cited by 292
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Liu, R., Oldham, R. J., Teal, E. L., Beers, S. A., & Cragg, M. S. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 248
Resistance to Antibody–Drug Conjugates
García‐Alonso, S., Ocaña, A., & Pandiella, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3671 · Cited by 220
New immune cell engagers for cancer immunotherapy
Fenis, A., Demaria, O., Gauthier, L., Vivier, É., & Narni-Mancinelli, É. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 214
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J. M., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 215
Pang, X., Huang, Z., Zhong, T., Zhang, P., Wang, Z. M., Xia, M., & Li, B. (2023) · mAbs · doi:10.1080/19420862.2023.2180794 · Cited by 202
Transferrin receptor targeting chimeras for membrane protein degradation
Zhang, D., Duque-Jimenez, J., Facchinetti, F., Brixi, G., Rhee, K., Feng, W. W., Janne, P. A., & Zhou, X. X. (2024) · Nature · doi:10.1038/s41586-024-07947-3 · Cited by 210
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 195
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Shim, H. (2020) · Biomolecules · doi:10.3390/biom10030360 · Cited by 179
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Martin-Alonso, C., Tabrizi, S., Xiong, K., Blewett, T., Sridhar, S., Crnjac, A., Patel, S., An, Z., Bekdemir, A., Shea, D., et al. (2024) · Science · doi:10.1126/science.adf2341 · Cited by 158
Boosting therapeutic potency of antibodies by taming Fc domain functions
Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 153
Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 142
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 138
Ion channels as therapeutic antibody targets
Hutchings, C. J., Colussi, P. A., & Clark, T. G. (2018) · mAbs · doi:10.1080/19420862.2018.1548232 · Cited by 131
Impact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 143
Fc-engineered antibodies with immune effector functions completely abolished
Wilkinson, I. C., Anderson, S., Fry, J. W., Julien, L. A., Neville, D. C. A., Qureshi, O. S., Watts, G., & Hale, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260954 · Cited by 127
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
Saha, R. P., Sharma, A. R., Singh, M. K., Samanta, S., Bhakta, S., Mandal, S., Bhattacharya, M., Lee, S. S., & Chakraborty, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01258 · Cited by 118
Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
Sun, L., Gao, F., Gao, Z., Ao, L., Li, N., Ma, S., Jia, M., Li, N., Lu, P., Sun, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001875 · Cited by 119
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 112
Ji, Y., Gao, Q., Ma, Y., Wang, F., Tan, X., Song, D., Hoo, R. L. C., Wang, Z., Ge, X., Han, H., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106720 · Cited by 114
Antozzi, C. G., Vu, T., Ramchandren, S., Nowak, R. J., Farmakidis, C., Bril, V., Bleecker, J. D., Yang, H., Minks, E., Park, J., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00498-8 · Cited by 111
Sifniotis, V., Cruz, E., Eroglu, B., & Kayser, V. (2019) · Antibodies · doi:10.3390/antib8020036 · Cited by 99
Sialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 104
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
Gauzy, L., Sassoon, I., & Brun, M. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220912955 · Cited by 87
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., Marco, A. D., et al. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6ws6/pdb · Cited by 82
Immunoglobulins or Antibodies: IMGT® Bridging Genes, Structures and Functions
Lefranc, M., & Lefranc, G. (2020) · Biomedicines · doi:10.3390/biomedicines8090319 · Cited by 83
Delidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Pinto, S., Pahl, J. H. W., Schottelius, A. J. G., Carter, P. J., & Koch, J. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.007 · Cited by 81
Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies
Chu, T. H., Crowley, A. R., Backes, I. M., Chang, C. H., Tay, M. Z., Broge, T. A., Tuyishime, M., Ferrari, G., Seaman, M. S., Richardson, S. I., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008083 · Cited by 80
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 86
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
Rassy, E., Rached, L., & Pistilli, B. (2022) · The Breast · doi:10.1016/j.breast.2022.10.016 · Cited by 77
Wang, Y., Zhang, X., Wang, Y., Zhao, W., Li, H., Zhang, L., Li, X., Zhang, T., Zhang, H., Huang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.004 · Cited by 76
Ahamadi-Fesharaki, R., Fateh, A., Vaziri, F., Solgi, G., Siadat, S. D., Mahboudi, F., & Jamnani, F. R. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.02.004 · Cited by 76
Complement C4 Prevents Viral Infection through Capsid Inactivation
Bottermann, M., Foss, S., Caddy, S., Clift, D., van Tienen, L. M., Vaysburd, M., Cruickshank, J., O’Connell, K., Clark, J., Mayes, K., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.016 · Cited by 75
Aoyama, M., Hashii, N., Tsukimura, W., Osumi, K., Harazono, A., Tada, M., Kiyoshi, M., Matsuda, A., & Ishii‐Watabe, A. (2019) · mAbs · doi:10.1080/19420862.2019.1608143 · Cited by 73
Temming, A. R., de Taeye, S. W., de Graaf, E. L., de Neef, L. A., Dekkers, G., Bruggeman, C. W., Koers, J., Ligthart, P. C., Nagelkerke, S. Q., Zimring, J. C., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900985 · Cited by 72
Wang, P., Gajjar, M. R., Yu, J., Padte, N. N., Gettie, A., Blanchard, J., Russell‐Lodrigue, K., Liao, L. E., Perelson, A. S., Huang, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008190117 · Cited by 71
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 75
Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V., & Cheung, N. V. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0121 · Cited by 69
Advances and challenges in therapeutic monoclonal antibodies drug development
dos Santos, M. L., Quintilio, W., Manieri, T. M., Tsuruta, L. R., & Moro, A. M. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000001007 · Cited by 70
Boustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2483 · Cited by 67
Suzuki, K., Tajima, M., Tokumaru, Y., Oshiro, Y., Nagata, S., Kamada, H., Kihara, M., Nakano, K., Honjo, T., & Ohta, A. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4947 · Cited by 64
Blueprint for antibody biologics developability
Mieczkowski, C., Zhang, X., Lee, D., Nguyen, K., Lv, W., Wang, Y., Zhang, Y., Way, J., & Gries, J. (2023) · mAbs · doi:10.1080/19420862.2023.2185924 · Cited by 65
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs
Groof, T. W. M. D., Bobkov, V., Heukers, R., & Smit, M. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.021 · Cited by 64
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Oostindie, S. C., van der Horst, H. J., Lindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., Burack, R., VanDerMeid, K. R., Strumane, K., Chamuleau, M. E. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207266 · Cited by 61
Peluso, M. O., Adam, A., Armet, C. M., Zhang, L., O’Connor, R. W., Lee, B. H., Lake, A. C., Normant, E., Chappel, S. C., Hill, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000413 · Cited by 61
Impact of IgG subclass on molecular properties of monoclonal antibodies
Tang, Y., Cain, P., Anguiano, V., Shih, J., Chai, Q., & Feng, Y. (2021) · mAbs · doi:10.1080/19420862.2021.1993768 · Cited by 59
Next generation of multispecific antibody engineering
Kéri, D., Walker, M., Singh, I., Nishikawa, K. K., & Garcés, F. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad027 · Cited by 59
Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Klapa, M. I., Candela, M., Rampelli, S., Lehoux, S. D., Lázaro, I., Sala‐Vila, A., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13773 · Cited by 60
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies
Briani, C., & Visentin, A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01222-x · Cited by 60
Andrews, N. P., Boeckman, J. X., Manning, C. F., Nguyen, J. T., Bechtold, H., Dumitras, C., Gong, B., Nguyen, K., van der List, D. A., Murray, K. D., et al. (2019) · eLife · doi:10.7554/elife.43322 · Cited by 52
Kelley, B. D. (2024) · mAbs · doi:10.1080/19420862.2024.2373330 · Cited by 53
Logic-gated antibody pairs that selectively act on cells co-expressing two antigens
Oostindie, S. C., Rinaldi, D. A., Zom, G. G., Wester, M. J., Paulet, D., Al-Tamimi, K., van der Meijden, E., Scheick, J. R., Wilpshaar, T. A., de Jong, B., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01384-1 · Cited by 51
Functional selection of protease inhibitory antibodies
Lopez, T., Mustafa, Z., Chen, C., Lee, K. B., Ramirez, A., Benitez, C., Luo, X., Ji, R., & Ge, X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903330116 · Cited by 51
VanDyke, D., Iglesias, M., Tomala, J., Young, A., Smith, J., Perry, J. A., Gebara, E., Cross, A. R., Cheung, L. S., Dykema, A. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111478 · Cited by 48
CD22 Blockage Restores Age-Related Impairments of Microglia Surveillance Capacity
Aires, V., Coulon-Bainier, C., Pavlovic, A., Ebeling, M., Schmucki, R., Schweitzer, C., Kueng, E., Gutbier, S., & Harde, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684430 · Cited by 48
Tolerance mechanisms of allergen immunotherapy
van de Veen, W., & Akdiş, M. (2019) · Allergy · doi:10.1111/all.14126 · Cited by 46
Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis
Fang, Q., Ou, J., & Nandakumar, K. S. (2019) · Mediators of Inflammation · doi:10.1155/2019/6363086 · Cited by 45
Hong, H., Han, L., Li, D., Gong, L., Zhou, K., Li, Y., Yu, H., Zhao, K., Shi, J., Zhou, Z., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202208773 · Cited by 44
Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 46
Cutting-edge approaches to B-cell depletion in autoimmune diseases
Robinson, W. H., Fiorentino, D. F., Chung, L. S., Moreland, L. W., Deodhar, M., Harler, M., Saulsbery, C., & Kunder, R. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454747 · Cited by 48
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Li, M., Zhao, R., Chen, J., Tian, W., Xia, C., Liu, X., Li, Y., Yan, Y., Li, S., Sun, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85329-9 · Cited by 45
The potential of engineered antibodies for HIV-1 therapy and cure
Grobben, M., Stuart, R. A., & van Gils, M. J. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.007 · Cited by 43
Vlahava, V.-M., Murrell, I., Zhuang, L., Aicheler, R., Lim, E. Y., Miners, K. L., Ladell, K., Suárez, N. M., Price, D. A., Davison, A. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139296 · Cited by 42
Modulating antibody effector functions by Fc glycoengineering
García-Alija, M., Moer, B. V., Sastre, D. E., Azzam, T., Du, J. J., Trastoy, B., Callewaert, N., Sundberg, E. J., & Guerin, M. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108201 · Cited by 43
Zhong, T., Zhang, L., Huang, Z., Pang, X., Jin, C., Liu, W., Du, J., Yin, W., Chen, N., Min, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111722 · Cited by 44
Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus
Jin, J., & Simmons, G. (2019) · Viruses · doi:10.3390/v11040305 · Cited by 40
Tajiri, M., Hashii, N., & Ishii‐Watabe, A. (2020) · Bioengineered · doi:10.1080/21655979.2020.1814683 · Cited by 39
Impact of N-Linked Glycosylation on Therapeutic Proteins
Chen, B., Liu, W., Li, Y., Ma, B., Shang, S., & Tan, Z. (2022) · Molecules · doi:10.3390/molecules27248859 · Cited by 39
Brennan, F. R., Polli, J. R., Sathish, J. G., Ramones, M., Wolf, B., Schlothauer, T., Peters, S. J., Maier, C. C., Ji, C., Wensel, D. L., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2505092 · Cited by 44
Self-citationWilkinson, I. C., & Hale, G. (2022) · mAbs · doi:10.1080/19420862.2022.2123299 · Cited by 41
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38
Reis, E. S., Buonpane, R. A., Celik, H., Marty, C., Lei, A., Jobe, F., Rupar, M. J., Zhang, Y., DiMatteo, D., Awdew, R., et al. (2024) · Blood · doi:10.1182/blood.2024024373 · Cited by 40
Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives
Mayrhofer, P., & Kunert, R. (2018) · Human Antibodies · doi:10.3233/hab-180347 · Cited by 41
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
Hale, G., Vos, J. D., Davy, A. D., Sandra, K., & Wilkinson, I. (2024) · mAbs · doi:10.1080/19420862.2024.2402701 · Cited by 36
de Jong, R. M., Meerstein‐Kessel, L., Da, D. F., Nsango, S. E., Challenger, J. D., van de Vegte‐Bolmer, M., van Gemert, G., Duarte, E. M., Teyssier, N., Sauerwein, R. W., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00366-9 · Cited by 36
Zhao, H., Wang, H., Zhou, Q., & Ren, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0029 · Cited by 36
Antibody recognition of bacterial surfaces and extracellular polysaccharides
Soliman, C., Pier, G. B., & Ramsland, P. A. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.12.001 · Cited by 34
Effect of UVC Irradiation on the Oxidation of Histidine in Monoclonal Antibodies
Miyahara, Y., Shintani, K., Hayashihara, K., Zukawa, T., Morita, Y., Nakazawa, T., Yoshida, T., Ohkubo, T., & Uchiyama, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-63078-5 · Cited by 35
Valente, D., Mauriac, C., Schmidt, T., Focken, I., Beninga, J., Mackness, B. C., Qiu, H., Vicat, P., Kandira, A., Radošević, K., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1829337 · Cited by 33
Glover, Z. K., Wecksler, A. T., Aryal, B., Mehta, S. C., Pegues, M. A., Chan, W., Lehtimaki, M., Luo, A., Sreedhara, A., & Rao, V. A. (2022) · mAbs · doi:10.1080/19420862.2022.2122957 · Cited by 33
Frey, G., Cugnetti, A. P. G., Liu, H., Xing, C., Wheeler, C. E., Chang, H. W., Boyle, W. J., & Short, J. M. (2024) · mAbs · doi:10.1080/19420862.2024.2322562 · Cited by 33
Karampatzakis, A., Brož, P., Rey, C., Önfelt, B., Matos, G. D. S. C. D., Rycroft, D., Ambrose, A. R., & Davis, D. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641521 · Cited by 33
Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 31
Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region
Handlogten, M. W., Peng, L., Christian, E. A., Xu, W., Lin, S., Venkat, R. V., Dall’Acqua, W. F., & Ahuja, S. (2020) · mAbs · doi:10.1080/19420862.2020.1779974 · Cited by 31
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 33
Metadata
- Authors
- Wang, X., Mathieu, M., & Brezski, R. J.
- Affiliations
- Genentech (US)
- Corresponding author
- Brezski, Randall J.
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-06
- Volume
- 9
- Issue
- 1
- Pages
- 63-73
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- PMC
- PMC5777978
- OpenAlex
- W2763907629
- Cited by
- 356
- References
- 95
- Citations by year
- 2026: 28 · 2025: 41 · 2024: 57 · 2023: 35 · 2022: 50 · 2021: 44 · 2020: 44 · 2019: 43 · 2018: 13 · 2017: 1
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Protein & Cell (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- antibody effector functions, human IgG1, therapeutic monoclonal antibodies, antibody engineering, immune effector mechanisms, antibody safety, antibody efficacy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Complement System Proteins, Humans, Immunoglobulin G, Receptors, Fc, Protein Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review